Overview

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Sunovion
Treatments:
Eszopiclone